According to the World Cancer Report Globocan 2020, recently published by the International Agency for Research on Cancer (IARC), part of the World Health Organization (WHO), 2.21 million people worldwide (18,673 people domestically) have died of lung cancer in 2020. The reason for this high mortality rate from lung cancer is that it has no symptoms, thus is difficult to diagnose early. More than 50% of people who have been diagnosed with an abnormality in their lungs are already in stages 3 or 4, and only about 30% of cases are operable.

As such, the best way to overcome lung cancer is an early diagnosis. However, the efficiency of early diagnosis is low. For example, the diagnosis rate of lung cancer through chest X-ray, which is mainly used for conventional lung cancer screening, is only 54%, the positive prediction rate is only 7.5%, the diagnosis rate of low-dose chest CT is 61.9%, and the positive prediction rate is only 35.7%. It also takes a lot of time and money for patients to visit the hospital in person and get a diagnosis via X-rays and CTs. CD Bio is a biotech company established to improve the uncomfortable environment and accuracy of these early diagnoses.

Eun-Sang Kwon, CTO of CD Bio and professor at the Research and Analytical Center for Giant Molecules, Tohoku Univ., Japan, has developed the patented technology of "Molecule Sensor and Cancer Diagnosis System using Molecule Sensor" and has introduced a next generation cancer diagnostic system based on this.

The molecular diagnostic technology presented by CD Bio is a cutting-edge technology that can diagnose lung cancer early in a single breath (exhalation). With ultra-precise diagnostic technology that enables accuracy at the ppt (1/10¹²) level, while the accuracy of other cancer sensors and diagnosticians is mainly at the ppm (1/10⁶) to ppb (1/10⁹) level, it has now become possible for anyone to diagnose cancer easily and conveniently without worrying about cost, and to increase the cancer cure rate and survival probability with rapid treatment through early diagnosis.

With its unique molecular diagnostic technology based on molecular physics and electrochemistry, CD Bio will strive to make a revolutionary change to the medical market paradigm for everyone to live a healthy and happy life without fear of cancer. Thank you for visiting CDBIO.

_{Kyung-Jin Baek,} CEO